Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Preferred Stock Liabilities (2021 - 2023)

TriSalus Life Sciences has reported Preferred Stock Liabilities over the past 3 years, most recently at $12.0 million for Q2 2023.

  • For Q2 2023, Preferred Stock Liabilities fell 95.18% year-over-year to $12.0 million; the TTM value through Jun 2023 reached $12.0 million, down 95.18%, while the annual FY2022 figure was $164.0 million, 2.18% up from the prior year.
  • Preferred Stock Liabilities for Q2 2023 was $12.0 million at TriSalus Life Sciences, down from $20.2 million in the prior quarter.
  • Over five years, Preferred Stock Liabilities peaked at $250.0 million in Q2 2022 and troughed at $12.0 million in Q2 2023.
  • A 3-year average of $145.8 million and a median of $164.0 million in 2022 define the central range for Preferred Stock Liabilities.
  • Biggest five-year swings in Preferred Stock Liabilities: grew 2.18% in 2022 and later tumbled 95.18% in 2023.
  • Year by year, Preferred Stock Liabilities stood at $160.5 million in 2021, then increased by 2.18% to $164.0 million in 2022, then plummeted by 92.66% to $12.0 million in 2023.
  • Business Quant data shows Preferred Stock Liabilities for TLSI at $12.0 million in Q2 2023, $20.2 million in Q1 2023, and $164.0 million in Q4 2022.